PVI
CRBP icon

Pura Vida Investments’s Corbus Pharmaceuticals CRBP Stock Holding History

Pura Vida Investments’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,667
Closed -$900K – 194
2020
Q3 		$900K Buy
+16,667
New +$3.02M 0.05% 132

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pura Vida Investments's CRBP Position: Q4 2020 in Review

Pura Vida Investments sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 16,273 shares — an estimated $879K sold.

Pura Vida Investments first reported a position in CRBP in Q1 2020 and held it in 2 quarters. The position peaked at $879K in Q3 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • Pura Vida Investments reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Pura Vida Investments sold 16,273 Corbus Pharmaceuticals shares in Q4 2020, an estimated $879K.
  • Pura Vida Investments first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Pura Vida Investments's Corbus Pharmaceuticals position peaked at $879K in Q3 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Pura Vida Investments's 13F filing for Q4 2020, filed 16 Feb 2021.